Characterization of CD103+ CD8+ tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade
Authors:
- 13 April 2020
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 69 (8) , 1493-1504
Abstract
Though therapy that promotes anti-tumor response about CD8+ tumor-infiltrating lymphocytes (TILs) has shown great potential, clinical responses to CD8+ TILs immunotherapy vary considerably, largely because of different subpopulation of CD8+ TILs exhibiting different biological characters. To define the relationship between subpopulation of CD8+ TILs and the outcome of antitumor reaction, the phenotype and function of CD103+ CD8+ TILs in esophageal squamous cell carcinoma (ESCC) were investigated. CD103+ CD8+ TILs were presented in ESCC, which displayed phenotype of tissue-resident memory T cells and exhibited high expression of immune checkpoints (PD-1, TIM-3). CD103+ CD8+ TILs were positively associated with the overall survivals of ESCC patients. This population of cells elicited potent proliferation and cytotoxic cytokine secretion potential. In addition, CD103+ CD8+ TILs were elicited potent anti-tumor immunity after anti-PD-1 blockade and were not affected by chemotherapy. This study emphasized the feature of CD103+ CD8+ TILs in immune response and identified potentially new targets in ESCC patients.Keywords
Funding Information
- National Science Foundation of China (U1604286, 81822043)
This publication has 46 references indexed in Scilit:
- Current status of cancer immunotherapy for esophageal squamous cell carcinomaEsophagus, 2017
- Immunotherapy for Esophageal Squamous Cell CarcinomaCurrent Oncology Reports, 2017
- Esophageal CarcinomaNew England Journal of Medicine, 2014
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancerNature Reviews Clinical Oncology, 2013
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThe Lancet Oncology, 2013
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalitiesThe Lancet Oncology, 2007
- Etiology and chemoprevention of esophageal squamous cell carcinomaCarcinogenesis, 2001